
There may be differences between this version and the published version. You are advised to consult the publisher’s version if you wish to cite from it.

https://eprints.gla.ac.uk/268534/

Deposited on: 4 April 2022
Thromboembolism and bleeding after covid-19

Frederick K Ho, lecturer¹, Jill P Pell, professor¹

¹. Institute of Health and Wellbeing, University of Glasgow, 1 Lilybank Gardens, G12 8RZ Glasgow, United Kingdom

Correspondence to: Frederick Ho Frederick.Ho@glasgow.ac.uk

Word count: 740

Competing interests: The BMJ has judged that there are no disqualifying financial ties to commercial companies.

It is now clear, from meta-analyses of case series (1, 2), cohort studies (3), and self-controlled case series (4, 5), that the risk of venous thromboembolism is elevated following SARS-CoV-2 infection. However, several important questions remain: for how long post-infection is the risk elevated, and does mild infection also confer increased risk? In this edition, Katsoularis and colleagues (doi: ) (6) address these questions by applying two complementary study designs to several Swedish registries.

Katsoularis and colleagues identified over one million individuals with laboratory-confirmed SARS-CoV-2 infection from the start of the pandemic to mid-2021 and over 4 million age-, sex- and country-matched individuals who had not had a positive test. Following adjustment for a wide range of potential confounders they reported a five-fold risk of deep vein thrombosis (relative incidence 4.98, 95% confidence interval 4.96-5.01), 33-fold risk of pulmonary embolism (relative incidence 33.05, 95% confidence interval 32.8-33.3), and almost 2-fold risk of bleeding (relative incidence 1.88, 95% confidence interval 1.71-2.07) in the 30 days following infection. The results were largely consistent when they applied a self-controlled case series approach; comparing the risk 30 days after infection with 30 days before. The benefit of this approach is that comparing two time periods in the same individual eliminates confounders that are stable over time, e.g. genetics (7).

The large study population enabled novel, granular analysis. Previous studies have already demonstrated that the association between SARS-CoV2-2 and thromboembolic events is much stronger for pulmonary embolism than deep vein thrombosis (8). Katsoularis and colleagues were able to show that the increased risk of thromboembolism also lasts longer for pulmonary embolism than deep vein thrombosis; 3 months for the latter compared with 6 months for the former. Consistent with previous studies, Katsoularis and colleagues demonstrated an increased risk of bleeding following SARS-CoV-2 infection. Use of thromboprophylaxis following SARS-CoV-2 infection clearly carries a risk of bleeding. However, COVID-19 has also been associated with coagulopathy and disseminated intravascular coagulation (9). Whilst not able to elucidate the underlying mechanism, they demonstrated that the association with bleeding was independent of anti-coagulation prior to SARS-CoV-2 infection and lasted for 2 months following it.

As this study showed that infection severity was associated with subsequent risk of thromboembolism and bleeding, COVID-19 vaccination could reduce the overall risk of thromboembolism both by preventing infection and reducing its severity when it does occur. Moreover, the findings of Katsoularis and colleagues help contextualise the risks and benefits of COVID-19 vaccination. Whilst there is a risk of thromboembolic events following vaccination (5, 10), the magnitude of risk is modest and persists for a shorter duration that that associated with infection. Are the study findings still relevant now that nearly 65% of the world’s population has received at least one vaccine dose (11)? Yes. Whilst current vaccines are highly effective against severe COVID-19, they produce only moderate reduction in the
risk of infection with the Omicron variant (12, 13). Even with a booster, breakthrough infections are common (14) and the effectiveness against symptomatic disease has been estimated to fall to less than 50% ten weeks after vaccination (13). While most infections with Omicron are mild owing the vaccination coverage, the results of this study, consistent with those of a previous self-controlled case series study (4), demonstrated increased risk of venous thromboembolism even among individuals with milder infection not requiring hospitalisation. Whilst their association was much weaker (relative incidence 5.87, 95% confidence interval 4.88-7.05 for pulmonary embolism) than that of hospitalised patients (relative incidence 64.49, 95% confidence interval 53.91-77.15) and those admitted to intensive care (relative incidence 196.98, 95% confidence interval 128.71-301.46), they account for a much larger proportion of SARS-CoV-2 infections (94.5% in this study). Therefore, they may nonetheless produce a significant number of thromboembolic events. An English study (15) reported a doubling in the incidence and mortality of thromboembolism since the start of pandemic in 2020 compared with the same periods in 2018 and 2019. Furthermore, it highlighted a similar magnitude of increase among individuals without positive test results. Whilst some of these people will have been infected prior to testing being available, others will have had mild or asymptomatic infection (16).

Notwithstanding the potential for new variants of concern, most governments around the world are removing restrictions and shifting focus to how we should ‘live with covid’ (17). Whilst this is an encouraging development, this study reminds us of the need to remain vigilant to the complications associated with even mild SARS-CoV-2 infection, such as thromboembolism.

**Copyright statement:** The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, a worldwide licence to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether known now or created in the future), to i) publish, reproduce, distribute, display and store the Contribution, ii) translate the Contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or, abstracts of the Contribution, iii) create any other derivative work(s) based on the Contribution, iv) to exploit all subsidiary rights in the Contribution, v) the inclusion of electronic links from the Contribution to third party material where-ever it may be located; and, vi) licence any third party to do any or all of the above.

**References**